HC Wainwright reaffirmed their buy rating on shares of Synlogic (NASDAQ:SYBX) in a research report report published on Monday, AnalystRatings.com reports. HC Wainwright currently has a $22.00 price target on the biotechnology company’s stock.
“We calculate an enterprise value of $820M, comprised of $620M for SYNB1020 in UCD and hyperammonemia and I/O portfolio. This yields a price objective of $22.00 per share, with approximately 37M fully-diluted shares outstanding as of mid-2020 (including exercise of approximately 2.5M outstanding options and all of the roughly 2.5M pre-funded warrants previously issued in the last private placement transaction). Risks include, but are not limited to: (1) feasibility issues with bridging the liquid to the solid oral formulation; (2) negative results from early trials; (3) slower-than-anticipated clinical testing; and (4) inability to obtain regulatory approvals.”,” HC Wainwright’s analyst commented.
Several other research analysts have also weighed in on SYBX. Chardan Capital set a $25.00 target price on shares of Synlogic and gave the stock a buy rating in a research note on Monday, July 15th. ValuEngine raised shares of Synlogic from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Synlogic from a hold rating to a buy rating and set a $9.00 price objective for the company in a research note on Tuesday, July 16th. Piper Jaffray Companies raised their price objective on shares of Synlogic from $16.00 to $20.00 and gave the company an overweight rating in a research note on Monday, July 15th. Finally, Jefferies Financial Group assumed coverage on shares of Synlogic in a research note on Tuesday, April 30th. They issued a buy rating and a $18.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $20.00.
Shares of SYBX stock opened at $4.52 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.53 and a quick ratio of 11.53. The firm has a market cap of $158.91 million, a PE ratio of -2.23 and a beta of 2.39. The company has a 50-day moving average of $6.99 and a two-hundred day moving average of $7.92. Synlogic has a 1-year low of $4.52 and a 1-year high of $14.59.
Synlogic (NASDAQ:SYBX) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.04. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. Synlogic had a negative net margin of 1,844.96% and a negative return on equity of 38.75%. Sell-side analysts anticipate that Synlogic will post -1.92 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can boosted its stake in shares of Synlogic by 5,743.1% in the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 12,520 shares during the period. Parametric Portfolio Associates LLC purchased a new position in shares of Synlogic in the second quarter valued at approximately $195,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Synlogic by 11.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 3,708 shares during the period. Bank of New York Mellon Corp lifted its stake in Synlogic by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 6,129 shares during the last quarter. Finally, Alps Advisors Inc. lifted its stake in Synlogic by 4.5% in the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 2,658 shares during the last quarter. 81.88% of the stock is owned by institutional investors and hedge funds.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Read More: How Does the Quiet Period Work?
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.